GlaxoSmithKline Pharmaceuticals Limited

NSEI:GLAXO Stock Report

Market Cap: ₹460.9b

GlaxoSmithKline Pharmaceuticals Valuation

Is GLAXO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GLAXO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GLAXO (₹2703) is trading above our estimate of fair value (₹1315.68)

Significantly Below Fair Value: GLAXO is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLAXO?

Other financial metrics that can be useful for relative valuation.

GLAXO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue12.6x
Enterprise Value/EBITDA45.7x
PEG Ratio2.8x

Price to Earnings Ratio vs Peers

How does GLAXO's PE Ratio compare to its peers?

The above table shows the PE ratio for GLAXO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average75.3x
AJANTPHARM Ajanta Pharma
48.4x14.7%₹408.4b
IPCALAB Ipca Laboratories
74.9x30.3%₹426.8b
500488 Abbott India
49.8x9.8%₹612.8b
SUVENPHAR Suven Pharmaceuticals
128.1x31.1%₹307.0b
GLAXO GlaxoSmithKline Pharmaceuticals
71.7x25.4%₹460.9b

Price-To-Earnings vs Peers: GLAXO is good value based on its Price-To-Earnings Ratio (71.7x) compared to the peer average (75.3x).


Price to Earnings Ratio vs Industry

How does GLAXO's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.2%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.2%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: GLAXO is expensive based on its Price-To-Earnings Ratio (71.7x) compared to the Indian Pharmaceuticals industry average (42.6x).


Price to Earnings Ratio vs Fair Ratio

What is GLAXO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLAXO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio71.7x
Fair PE Ratio50.7x

Price-To-Earnings vs Fair Ratio: GLAXO is expensive based on its Price-To-Earnings Ratio (71.7x) compared to the estimated Fair Price-To-Earnings Ratio (50.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GLAXO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹2,703.00
₹2,933.75
+8.5%
8.8%₹3,250.00₹2,640.00n/a4
Oct ’25₹2,735.35
₹2,908.75
+6.3%
9.7%₹3,250.00₹2,620.00n/a4
Sep ’25₹2,745.10
₹2,908.75
+6.0%
9.7%₹3,250.00₹2,620.00n/a4
Aug ’25₹2,758.25
₹2,694.25
-2.3%
11.6%₹3,012.00₹2,380.00n/a4
Jul ’25₹2,605.20
₹2,694.25
+3.4%
11.6%₹3,012.00₹2,380.00n/a4
Jun ’25₹2,619.30
₹2,598.50
-0.8%
11.1%₹3,000.00₹2,270.00n/a4
May ’25₹2,086.75
₹2,141.25
+2.6%
9.7%₹2,450.00₹1,895.00n/a4
Apr ’25₹1,986.30
₹2,141.25
+7.8%
9.7%₹2,450.00₹1,895.00n/a4
Mar ’25₹2,147.10
₹2,141.25
-0.3%
9.7%₹2,450.00₹1,895.00n/a4
Feb ’25₹2,228.05
₹1,783.80
-19.9%
19.5%₹2,450.00₹1,490.00n/a5
Jan ’25₹1,951.55
₹1,566.80
-19.7%
5.3%₹1,669.00₹1,480.00n/a5
Dec ’24₹1,678.15
₹1,566.80
-6.6%
5.3%₹1,669.00₹1,480.00n/a5
Nov ’24₹1,406.85
₹1,434.00
+1.9%
8.3%₹1,575.00₹1,215.00n/a5
Oct ’24₹1,548.25
₹1,408.00
-9.1%
9.2%₹1,575.00₹1,215.00₹2,735.355
Sep ’24₹1,438.30
₹1,408.00
-2.1%
9.2%₹1,575.00₹1,215.00₹2,745.105
Aug ’24₹1,405.00
₹1,425.00
+1.4%
8.7%₹1,575.00₹1,215.00₹2,758.256
Jul ’24₹1,425.10
₹1,354.17
-5.0%
8.6%₹1,510.00₹1,215.00₹2,605.206
Jun ’24₹1,327.20
₹1,340.14
+1.0%
8.4%₹1,510.00₹1,215.00₹2,619.307
May ’24₹1,241.90
₹1,353.43
+9.0%
8.6%₹1,510.00₹1,145.00₹2,086.757
Apr ’24₹1,324.75
₹1,352.00
+2.1%
8.5%₹1,500.00₹1,145.00₹1,986.307
Mar ’24₹1,336.50
₹1,380.57
+3.3%
7.7%₹1,500.00₹1,145.00₹2,147.107
Feb ’24₹1,250.00
₹1,484.00
+18.7%
9.6%₹1,690.00₹1,226.00₹2,228.057
Jan ’24₹1,318.75
₹1,518.29
+15.1%
13.4%₹1,930.00₹1,226.00₹1,951.557
Dec ’23₹1,319.20
₹1,518.29
+15.1%
13.4%₹1,930.00₹1,226.00₹1,678.157
Nov ’23₹1,378.60
₹1,597.14
+15.9%
13.1%₹1,930.00₹1,378.00₹1,406.857
Oct ’23₹1,424.40
₹1,604.29
+12.6%
13.0%₹1,930.00₹1,378.00₹1,548.257

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies